(Q33315244)

25 July 2017

title

Retroviral vectors for clinical immunogene therapy are stable for up to 9 years (English)

1 reference

25 July 2017

C H J Lamers

1

1 reference

25 July 2017

P van Elzakker

2

1 reference

25 July 2017

B A Luider

3

1 reference

25 July 2017

S C L van Steenbergen

4

1 reference

25 July 2017

S Sleijfer

5

1 reference

25 July 2017

R Debets

6

1 reference

25 July 2017

J W Gratama

7

1 reference

25 July 2017

publication date

18 January 2008

1 reference

25 July 2017

1 reference

25 July 2017

volume

15

1 reference

25 July 2017

issue

4

1 reference

25 July 2017

page(s)

268-274

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7701114

25 July 2017

exact match

0 references

cites work

Retroviral vectors for human gene delivery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Progress and problems with the use of viral vectors for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydras

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

The temperature stability of mouse retroviruses depends on the cholesterol levels of viral lipid shell and cellular plasma membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Relationship between retroviral vector membrane and vector stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Effect of medium sugar source on the production of retroviral vectors for gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Effect of osmotic pressure on the production of retroviral vectors: Enhancement in vector stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Retrovirus producer cell line metabolism: implications on viral productivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Optimized conditions for the production of recombinant amphotropic retroviral vector preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Kinetic analyses of stability of simple and complex retroviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Clinical grade vector production: analysis of yield, stability, and storage of gmp-produced retroviral vectors for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Determination of Infectious Retrovirus Concentration from Colony-Forming Assay with Quantitative Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Rapid titer determination using quantitative real-time PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Application of the polymerase chain reaction in determination of recombinant retrovirus titers as fifty percent endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

State-of-the-art of the production of retroviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Lipid composition and fluidity of the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Amphotropic murine leukaemia virus envelope protein is associated with cholesterol-rich microdomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Gene expression analysis of murine cells producing amphotropic mouse leukaemia virus at a cultivation temperature of 32 and 37 degrees C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Screening of novel excipients for improving the stability of retroviral and adenoviral vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

Kinetics of retrovirus production and decay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

inferred from DOI database lookup

7 January 2021

based on heuristic

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

inferred from DOI database lookup

7 January 2021

based on heuristic

Internal image anti-idiotype antibodies related to renal-cell carcinoma-associated antigen G250

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701114

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.CGT.7701114

1 reference

25 July 2017

1 reference